|
Sign In to gain access to subscriptions and/or personal tools.
|
Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy
Mark F. McCarty
NutriGuard Research, Encinitas, California, mccarty{at}pantox.com
The aberrant behavior of cancer reflects upregulation of certain oncogenic signaling pathways that promote proliferation, inhibit apoptosis, and enable the cancer to spread and evoke angiogenesis. Theoretically, it should be feasible to decrease the activity of these pathways—or increase the activity of pathways that oppose them—with noncytotoxic agents. Since multiple pathways are dysfunctional in most cancers, and cancers accumulate new oncogenic mutations as they progress, the greatest and most durable therapeutic benefit will likely be achieved with combination regimens that address several targets. Thus, a multifocal signal modulation therapy (MSMT) of cancer is proposed. This concept has already been documented by researchers who have shown that certain combinations of signal modulators—of limited utility when administered individually—can achieve dramatic suppression of tumor growth in rodent xenograft models. The present essay attempts to guide development of MSMTs for prostate cancer. Androgen ablation is a signal-modulating measure already in standard use in the management of delocalized prostate cancer. The additional molecular targets considered here include the type 1 insulin-like growth factor receptor, the epidermal growth factor receptor, mammalian target of rapamycin, NF- B, hypoxia-inducible factor-1 , hsp90, cyclooxygenase-2, protein kinase A type I, vascular endothelial growth factor, 5-lipoxygenase, 12-lipoxygenase, angiotensin II receptor type 1, bradykinin receptor type 1, c-Src, interleukin-6, ras, MDM2, bcl-2/bclxL, vitamin D receptor, estrogen receptor-ß, and PPAR-. Various nutrients and phytochemicals suspected to have potential utility in prostate cancer prevention and therapy, but whose key molecular targets are still unknown, might reasonably be incorporated into MSMTs for prostate cancer; these include lycopene, selenium, green tea polyphenols, genistein, and silibinin. MSMTs can be developed systematically by testing various combinations of signal-modulating agents, in concentrations that can feasibly be achieved and maintained clinically, on human prostate cancer cell lines; combinations that appear promising can then be tested in xenograft models and, ultimately, in the clinic. Some signal modulators can increase response to cytotoxic drugs by upregulating effectors of apoptosis. When MSMTs fail to raise the spontaneous apoptosis rate sufficiently to achieve tumor stasis or regression, incorporation of appropriate cytotoxic agents into the regimen may improve the clinical outcome.
Key Words: prostate cancer • signal modulation • IGF-I, TOR • hsp 90 • cyclooxy genase-2 • c-Src • NF-kappa B
Integrative Cancer Therapies, Vol. 3, No. 4,
349-380 (2004)
DOI: 10.1177/1534735404270757
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Hanaka, S.-C. Pawelzik, J. I. Johnsen, M. Rakonjac, K. Terawaki, A. Rasmuson, B. Sveinbjornsson, M. C. Schumacher, M. Hamberg, B. Samuelsson, et al.
Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells
PNAS,
November 3, 2009;
106(44):
18757 - 18762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Tatarov, T. J. Mitchell, M. Seywright, H. Y. Leung, V. G. Brunton, and J. Edwards
Src Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer
Clin. Cancer Res.,
May 15, 2009;
15(10):
3540 - 3549.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Saleem, I. Murtaza, R. S. Tarapore, Y. Suh, V. M. Adhami, J. J. Johnson, I. A. Siddiqui, N. Khan, M. Asim, B. B. Hafeez, et al.
Lupeol inhibits proliferation of human prostate cancer cells by targeting {beta}-catenin signaling
Carcinogenesis,
May 1, 2009;
30(5):
808 - 817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Jain, G. Chakraborty, R. Raja, S. Kale, and G. C. Kundu
Prostaglandin E2 Regulates Tumor Angiogenesis in Prostate Cancer
Cancer Res.,
October 1, 2008;
68(19):
7750 - 7759.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-M. Chen, T. E. Spratt, B. A. Stanley, D. A. De Cotiis, M. C. Bewley, J. M. Flanagan, D. Desai, A. Das, E. S. Fiala, S. Amin, et al.
Inhibition of Nuclear Factor-{kappa}B DNA Binding by Organoselenocyanates through Covalent Modification of the p50 Subunit
Cancer Res.,
November 1, 2007;
67(21):
10475 - 10483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Kumar, S. Bhaskaran, M. Ganapathy, K. Crosby, M. D. Davis, P. Kochunov, J. Schoolfield, I-T. Yeh, D. A. Troyer, and R. Ghosh
Akt/cAMP-Responsive Element Binding Protein/Cyclin D1 Network: A Novel Target for Prostate Cancer Inhibition in Transgenic Adenocarcinoma of Mouse Prostate Model Mediated by Nexrutine, a Phellodendron Amurense Bark Extract
Clin. Cancer Res.,
May 1, 2007;
13(9):
2784 - 2794.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. M. Adhami, A. Malik, N. Zaman, S. Sarfaraz, I. A. Siddiqui, D. N. Syed, F. Afaq, F. S. Pasha, M. Saleem, and H. Mukhtar
Combined Inhibitory Effects of Green Tea Polyphenols and Selective Cyclooxygenase-2 Inhibitors on the Growth of Human Prostate Cancer Cells Both In vitro and In vivo
Clin. Cancer Res.,
March 1, 2007;
13(5):
1611 - 1619.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Chouinard, G. Pelletier, A. Belanger, and O. Barbier
Isoform-Specific Regulation of Uridine Diphosphate-Glucuronosyltransferase 2B Enzymes in the Human Prostate: Differential Consequences for Androgen and Bioactive Lipid Inactivation
Endocrinology,
November 1, 2006;
147(11):
5431 - 5442.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. S. R. Sastry, Y. Karpova, and G. Kulik
Epidermal Growth Factor Protects Prostate Cancer Cells from Apoptosis by Inducing BAD Phosphorylation via Redundant Signaling Pathways
J. Biol. Chem.,
September 15, 2006;
281(37):
27367 - 27377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P Singh and R. Agarwal
Mechanisms of action of novel agents for prostate cancer chemoprevention.
Endocr. Relat. Cancer,
September 1, 2006;
13(3):
751 - 778.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. McCarty and K. I. Block
Preadministration of High-Dose Salicylates, Suppressors of NF-{kappa}B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy
Integr Cancer Ther,
September 1, 2006;
5(3):
252 - 268.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Li, L. Wu, and Z. Zhang
Constructing biological networks through combined literature mining and microarray analysis: a LMMA approach
Bioinformatics,
September 1, 2006;
22(17):
2143 - 2150.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Jain, G. Chakraborty, and G. C. Kundu
The Crucial Role of Cyclooxygenase-2 in Osteopontin-Induced Protein Kinase C {alpha}/c-Src/I{kappa}B Kinase {alpha}/{beta}-Dependent Prostate Tumor Progression and Angiogenesis.
Cancer Res.,
July 1, 2006;
66(13):
6638 - 6648.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Pienta and D. Bradley
Mechanisms underlying the development of androgen-independent prostate cancer.
Clin. Cancer Res.,
March 15, 2006;
12(6):
1665 - 1671.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Lin, P. L. Zhang, X. J. Yang, J. W. Prichard, M. Lun, and R. E. Brown
Morphoproteomic and Molecular Concomitants of an Overexpressed and Activated mTOR Pathway in Renal Cell Carcinomas
Ann. Clin. Lab. Sci.,
January 1, 2006;
36(3):
283 - 293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Rennebeck, M. Martelli, and N. Kyprianou
Anoikis and Survival Connections in the Tumor Microenvironment: Is There a Role in Prostate Cancer Metastasis?
Cancer Res.,
December 15, 2005;
65(24):
11230 - 11235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. McCarty and K. I. Block
Multifocal Angiostatic Therapy: An Update
Integr Cancer Ther,
December 1, 2005;
4(4):
301 - 314.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. D. Loberg, C. J. Logothetis, E. T. Keller, and K. J. Pienta
Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype
J. Clin. Oncol.,
November 10, 2005;
23(32):
8232 - 8241.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-T. Huang, S.-L. Pan, J.-H. Guh, Y.-L. Chang, F.-Y. Lee, S.-C. Kuo, and C.-M. Teng
YC-1 suppresses constitutive nuclear factor-{kappa}B activation and induces apoptosis in human prostate cancer cells
Mol. Cancer Ther.,
October 1, 2005;
4(10):
1628 - 1635.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Pienta and D. C. Smith
Advances in Prostate Cancer Chemotherapy: A New Era Begins
CA Cancer J Clin,
September 1, 2005;
55(5):
300 - 318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
